

Additional file 3  
Table S1

<b>CHARACTERISTICS</b>	<b>Without recurrence No. (%)</b>	<b>With recurrence No. (%)</b>
<b>Total cases</b>	52 (100)	58 (100)
<b>Age (years)</b>		
≤ 56.5	25 (48.1)	30 (51.7)
> 56.5	27 (51.9)	28 (48.3)
<b>Menopausal status</b>		
Premenopausal	17 (32.7)	17 (29.3)
Postmenopausal	35 (67.3)	41 (70.7)
<b>Tumoral size</b>		
T1	27 (51.9)	25 (43.1)
T2	25 (48.1)	33 (56.9)
<b>Nodal status</b>		
N (-)	27 (51.9)	25 (43.1)
N (+)	25 (48.1)	33 (56.9)
<b>Histological grade</b>		
Well Dif. (I)	19 (36.5)	13 (22.4)
Mod. Dif. (II)	27 (51.9)	26 (44.8)
Poorly Dif. (III)	6 (11.5)	19 (32.8)
<b>Nottingham prognostic index</b>		
<3.4	25 (48.1)	14 (24.1)
3.4-5.4	21 (40.4)	32 (55.2)
>5.4	6 (11.5)	12 (20.7)
<b>Estrogen Receptor</b>		
Negative	15 (28.8)	31 (53.4)
Positive	37 (71.2)	27 (46.6)
<b>Progesterone Receptor</b>		
Negative	19 (36.5)	39 (67.2)
Positive	33 (63.5)	19 (32.8)
<b>Adjuvant radiotherapy</b>		
No	40 (76.9)	32 (55.2)
Yes	12 (23.1)	26 (44.8)
<b>Adjuvant systemic therapy</b>		
Chemotherapy	14 (26.9)	25 (43.1)
Tamoxifen	21 (40.4)	14 (24.1)
Chemotherapy plus sequential Tamoxifen	10 (19.2)	6 (10.3)
No treatment	7 (13.5)	13 (22.4)
<b>HER2 Status</b>		
Negative	43 (82.7)	48 (82.8)
Positive	9 (17.3)	10 (17.2)
<b>Basal like phenotype</b>		
Non basal like	43 (82.7)	37 (63.8)
Basal like	9 (17.3)	21 (36.2)